Darbepoetin alfa biosimilar - 3SBio

Drug Profile

Darbepoetin alfa biosimilar - 3SBio

Alternative Names: NuPIAO; Recombinant erythropoiesis stimulating protein - 3SBio; Recombinant erythropoietin stimulating protein - 3SBio; Recombinant erythropoietin stimulating protein - Shenyang Sunshine

Latest Information Update: 13 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 3SBio
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Anaemia

Most Recent Events

  • 01 Jun 2016 3SBio completes phase I clinical trials for Anaemia in China (ChiCTR-ONRC12003868 and ChiCTR-ONRC-12003869)
  • 29 Apr 2016 Biomarkers information updated
  • 26 Apr 2016 Phase-I development is ongoing in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top